2 weeks Ago By ABMN Staff
Norges Bank purchased a new position in shares of Innoviva, Inc. ( NASDAQ:INVA – Free Report ) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 85,282 shares of the biotechnology company’s stock, valued at approximately $1,480,000.
Norges Bank owned approximately 0.14% of Innoviva as of its most recent filing with the Securities & Exchange Commission. Several other hedge funds have also recently added to or reduced their stakes in the company.
Barclays PLC raised its holdings in Innoviva by 254.2% in the 3rd quarter. Barclays PLC now owns 100,594 shares of the biotechnology company’s stock valued at $1,942,000 after acquiring an additional 72,192 shares during the last quarter.
Jane Street Group LLC lifted its position in Innoviva by 46.4% during the third quarter. Jane Street Group LLC now owns 136,361 shares of the biotechnology company’s stock worth $2,633,000 after buying an additional 43,218 shares in the last quarter.
FMR LLC boosted its stake in Innoviva by 8.2% during the third quarter. FMR LLC now owns 10,119 shares of the biotechnology company’s stock worth $195,000 after buying an additional 771 shares during the last quarter.
JPMorgan Chase & Co. boosted its position in shares of Innoviva by 14.2% during the 3rd quarter.
JPMorgan Chase & Co. now owns 578,243 shares of the biotechnology company’s stock valued at $11,166,000 after acquiring an additional 72,039 shares during the last quarter. Finally, Entropy Technologies LP purchased a new stake in shares of Innoviva in the fourth quarter valued at about $248,000.
99.12% of the stock is owned by institutional investors and hedge funds. Insider Transactions at Innoviva In other news, major shareholder Alexander J.
Denner sold 1,196,746 shares of the stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $17.52, for a total transaction of $20,966,989.
92. Following the sale, the insider now owns 5,658,705 shares of the company’s stock, valued at approximately $99,140,511.60.
This represents a 17.46 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website .
Company insiders own 1.70% of the company’s stock. Wall Street Analyst Weigh In Get Our Latest Analysis on Innoviva Innoviva Trading Up 2.
5 % NASDAQ INVA opened at $17.52 on Friday. The company has a debt-to-equity ratio of 0.
38, a current ratio of 1.79 and a quick ratio of 1.64.
The stock has a market capitalization of $1.10 billion, a P/E ratio of 25.39 and a beta of 0.
48. The firm’s 50-day moving average is $17.73 and its two-hundred day moving average is $18.
49. Innoviva, Inc. has a 12 month low of $14.
33 and a 12 month high of $21.28. Innoviva ( NASDAQ:INVA – Get Free Report ) last issued its quarterly earnings data on Wednesday, February 26th.
The biotechnology company reported $0.57 EPS for the quarter. Innoviva had a net margin of 18.
31% and a return on equity of 20.84%. The firm had revenue of $91.
81 million for the quarter. On average, sell-side analysts anticipate that Innoviva, Inc. will post 0.
33 earnings per share for the current year. About Innoviva ( Free Report ) Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.
Featured Stories Want to see what other hedge funds are holding INVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Innoviva, Inc. ( NASDAQ:INVA – Free Report ).
Receive News & Ratings for Innoviva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva and related companies with MarketBeat.com's FREE daily email newsletter ..
